HERBERT J. CONRAD - Corporate Board Profile

Celldex Therapeutics, Inc.

Filing Date	Source Excerpt
2008-08-25	Herbert J. Conrad became a director of AVANT upon consummation of the Merger with Celldex. Mr. Conrad had been a director of Celldex since March 2004. ... The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chairman, Karen Shoos Lipton and Charles R. Schaller. ... Directors who are not employees of AVANT are each entitled to receive a retainer fee of $20,000 each fiscal year. ... This table summarizes the annual cash compensation for AVANTs non-employee directors during 2007. Karen Shoos Lipton $38,125 ...
2009-11-06	Herbert J. Conrad Age 77 Year First Became Director 2008. Mr. Conrad became a director of Celldex in 2008 upon consummation of the merger of Celldex Research and Celldex. The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chairman, Larry Ellberger, Karen Shoos Lipton and Charles R. Schaller. The Director Compensation table shows Herbert J. Conrad with total compensation of $134,981.
2010-08-04	Herbert J. Conrad became a director of Celldex in March 2008. The Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chairman, Karen Shoos Lipton, Larry Ellberger and Charles R. Schaller. The following table summarizes the annual compensation for our non-employee directors during 2009. Herbert J. Conrad 80,000 Fees Earned or Paid in Cash, 8,960 Stock Awards, Total 88,960.
2011-04-26	Herbert J. Conrad became a director of Celldex in March 2008. He is Chairman of the Board of Pharmasset, Inc. and a member of its Audit and Nominating and Corporate Governance Committees. The Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chairman, Larry Ellberger and Karen Shoos Lipton. The following table summarizes the annual compensation for our non-employee directors during 2010. Herbert J. Conrad 80,000 Fees Earned or Paid in Cash, 7,920 Stock Awards, Total 87,920.
2012-04-24	Herbert J. Conrad became a director of Celldex in March 2008 upon consummation of the AVANT Merger. The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chairman, Larry Ellberger and Karen L. Shoos. The following table summarizes the annual compensation for our non-employee directors during 2011. Herbert J. Conrad Fees Earned or Paid in Cash $80,000 Stock Awards $6,480 Total $86,480
2013-04-23	Herbert J. Conrad became a director of Celldex in March 2008 upon consummation of the AVANT Merger. The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chair, Larry Ellberger and Karen L. Shoos. The following table summarizes the annual compensation for our non-employee directors during 2012. Herbert J. Conrad Fees Earned or Paid in Cash $80,000 Stock Awards $9,000 Total $89,000
2014-04-09	Herbert J. Conrad 81 2008 The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chair, Larry Ellberger and Karen L. Shoos. The following table summarizes the annual compensation for our non-employee directors during 2013. Herbert J. Conrad 80,000 30,400 19,481 129,881
2015-04-23	Herbert J. Conrad became a director of Celldex in March 2008. The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Karen L. Shoos and Richard van den Broek. The following table summarizes the annual compensation for our non- employee directors during 2014. Herbert J. Conrad Fees Earned or Paid in Cash $80,000 Stock Awards $26,900 Option Awards $17,370 Total $124,270.
2016-04-21	Herbert J. Conrad Age 83 Year First Became Director 2008. Mr. Conrad serves as Chair of the Nominating and Corporate Governance Committee. Director Compensation Table shows total compensation $405,975.
2017-04-28	Herbert J. Conrad became a director of Celldex in March 2008. The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The Nominating and Corporate Governance Committee currently consisting of Karen L. Shoos, Chair, Herbert J. Conrad and Larry Ellberger. The following table summarizes the annual compensation for our non-employee directors during 2016. Herbert J. Conrad Fees Earned or Paid in Cash $76,250 Stock Awards $47,200 Option Awards $47,256 Total $170,706
2018-04-30	Herbert J. Conrad Age 85 Year First Became Director 2008 The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Karen L. Shoos, Chair, Herbert J. Conrad and Larry Ellberger. The following table summarizes the annual compensation for our non-employee directors during 2017. Herbert J. Conrad Fees Earned or Paid in Cash $75,000 Stock Awards $23,200 Option Awards $23,345 Total $121,545
2019-04-26	Herbert J. Conrad became a director of Celldex in March 2008. He is a member of the Compensation Committee and the Nominating and Corporate Governance Committee. Compensation for 2018 was $91,844.
2020-04-28	Herbert J. Conrad became a director of Celldex in March 2008. The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Keith L. Brownlie and Karen L. Shoos. The following table summarizes the annual compensation for our non-employee directors during 2019. Herbert J. Conrad received $53,054 in fees and $9,386 in option awards, totaling $62,440.
2021-04-27	Herbert J. Conrad became a director of Celldex in March 2008 upon consummation of the AVANT Merger. Mr. Conrad was President of the U.S. Pharmaceuticals Division of Hoffmann-La Roche, Inc., a pharmaceutical company, from 1982 until his retirement in 1993. ... The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. ... The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Keith L. Brownlie and Karen L. Shoos. ... The following table summarizes the annual compensation for our non-employee directors during 2020. Herbert J. Conrad Fees Earned or Paid in Cash $54,250 Option Awards $87,586 Total $141,836.
2022-04-26	Herbert J. Conrad became a director of Celldex in March 2008 upon consummation of our merger with AVANT. ... The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. ... The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Keith L. Brownlie and Karen L. Shoos. ... The following table summarizes the annual compensation for our non-employee directors during 2021. ... Herbert J. Conrad Fees Earned or Paid in Cash ($) 54,250 Option Awards ($) 260,828 Total ($) 315,078.
2023-04-25	Herbert J. Conrad 90 2008 2 The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Cheryl L. Cohen and Garry Neil, M.D. The following table summarizes the annual compensation for our non-employee directors during 2022. Herbert J. Conrad Fees Earned or Paid in Cash ($) 53,505 Option Awards ($) 231,866 Total ($) 285,371
2024-04-25	The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Rita Jain, M.D. and Garry Neil, M.D. ... The amounts in the Option Awards column reflect the grant date fair value in accordance with U.S. GAAP of stock option awards made in 2023 to each of our non-employee directors for awards pursuant to the 2021 Incentive Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of forfeiture (so long as the director remains a member of the Board as of such date).